DataMeds AI buys Helomics cancer diagnostics lab from Axe Compute for USD 1.5 million

• DataMEDS AI completed the acquisition of Helomics, a Pittsburgh-based AI cancer diagnostics lab, from Axe Compute on Sept. 15, 2026.
• Purchase price totaled $1.5 million, paid with DataMEDS common shares and an acquisition note.
• Assets include a CLIA/CAP-certified clinical laboratory, related equipment, and a precision oncology CRO central lab services business.
• The deal also transferred $1.5 million in cash; Helomics came with no third-party debt requiring repayment.
• Transaction broadens DataMEDS into oncology, with plans to expand beyond tumor profiling into cancer screening and traditional CLIA lab services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042951), on September 16, 2026, and is solely responsible for the information contained therein.